Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
Venus Concept files to sell 15.58M shares of common stock for holders  16:43
04/17/20
04/17
16:43
04/17/20
16:43
VERO

Venus Concept

$4.27 /

-0.02 (-0.47%)

 
ShowHide Related Items >><<
VERO Venus Concept
$4.27 /

-0.02 (-0.47%)

03/31/20
Fly Intel: Top five analyst downgrades
03/31/20 Oppenheimer
Venus Concept downgraded to Perform at Oppenheimer as COVID-19 clouds outlook
03/31/20 Oppenheimer
Venus Concept downgraded to Perform from Outperform at Oppenheimer
01/09/20 Oppenheimer
Oppenheimer says has 'fundamentally positive' stance on Venus Concept
Hot Stocks
Venus Concept 510(k) premarket notification posted by FDA » 11:19
04/06/20
04/06
11:19
04/06/20
11:19
VERO

Venus Concept

$3.93 /

+0.23 (+6.22%)

The FDA issued a…

The FDA issued a "Substantially Equivalent" decision on April 1 for the Venus Viva system based on the application made by Venus Concept USA, according to a 510(k) Premarket Notification posted to the FDA website. Reference Link

ShowHide Related Items >><<
VERO Venus Concept
$3.93 /

+0.23 (+6.22%)

03/31/20
Fly Intel: Top five analyst downgrades
03/31/20 Oppenheimer
Venus Concept downgraded to Perform at Oppenheimer as COVID-19 clouds outlook
03/31/20 Oppenheimer
Venus Concept downgraded to Perform from Outperform at Oppenheimer
01/09/20 Oppenheimer
Oppenheimer says has 'fundamentally positive' stance on Venus Concept
Downgrade
Fly Intel: Top five analyst downgrades » 10:10
03/31/20
03/31
10:10
03/31/20
10:10
AMRN

Amarin

$4.05 /

-9.54 (-70.20%)

, HEXO

Hexo

$0.85 /

+0.0729 (+9.38%)

, BKR

Baker Hughes

$10.91 /

-0.03 (-0.27%)

, VERO

Venus Concept

$3.25 /

-0.4 (-10.96%)

, CRON

Cronos Group

$5.99 /

-0.37 (-5.82%)

downgraded Cronos Group…

downgraded Cronos Group Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Amarin (AMRN) downgraded to Hold from Buy at Jefferies with analyst Michael Yee expecting the stock to be range-bound until there is more clarity on an appeal to last night's negative patent decision and scenarios where generics may not immediately hit. 2. Hexo (HEXO) downgraded to Hold from Buy at Desjardins with analyst John Chu saying near-term funding requirements overshadow better than expected Q2 adjusted EBITDA loss as the company will need up to C$55M in equity financing by April 30. 3. Baker Hughes (BKR) downgraded to Hold from Buy at Argus withanalyst Bill Selesky warning that dramatically lower crude oil prices and demand impact of COVID-19 will lead to greater oil supply imbalances and a sharp deceleration in drilling activity starting in Q2. 4. Venus Concept (VERO) downgraded to Perform from Outperform at Oppenheimer as COVID-19 clouds outlook with analyst Suraj Kalia noting that the COVID-19 situation has forced the company to pull fiscal year 2020 guidance, therefore leaving a level of uncertainty in numbers. 5. Cronos Group (CRON) downgraded to Sell from Hold at Canaccord with analyst sayinh Q4 results came in below expectations on a modest top-line improvement, inventory write-offs, and deepening adjusted EBITDA losses. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
AMRN Amarin
$4.05 /

-9.54 (-70.20%)

03/31/20
upgraded Fly Intel: Top five analyst upgrades
03/31/20 JPMorgan
Amarin shares could recover over time, says JPMorgan
03/31/20 Oppenheimer
Oppenheimer upgrades Amarin to Perform with shares poised for 70% drop at open
03/31/20 Citi
Amarin legal defeat 'major negative' for shares, says Citi
HEXO Hexo
$0.85 /

+0.0729 (+9.38%)

03/31/20 BofA
Hexo resumed with an Underperform at BofA
03/31/20 Desjardins
Hexo downgraded to Hold from Buy at Desjardins
03/18/20 BMO Capital
Hexo downgraded to Underperform from Market Perform at BMO Capital
03/18/20 AltaCorp
Hexo downgraded to Underperform from Sector Perform at AltaCorp
BKR Baker Hughes
$10.91 /

-0.03 (-0.27%)

03/31/20 Argus
Baker Hughes downgraded to Hold from Buy at Argus
03/31/20 Argus
Baker Hughes downgraded to Hold from Buy at Argus
03/30/20 BofA
US 1 List changes at BofA
03/30/20 Wells Fargo
Baker Hughes price target lowered to $18 from $25 at Wells Fargo
VERO Venus Concept
$3.25 /

-0.4 (-10.96%)

03/31/20 Oppenheimer
Venus Concept downgraded to Perform at Oppenheimer as COVID-19 clouds outlook
03/31/20 Oppenheimer
Venus Concept downgraded to Perform from Outperform at Oppenheimer
01/09/20 Oppenheimer
Oppenheimer says has 'fundamentally positive' stance on Venus Concept
01/09/20 Oppenheimer
Venus Concept initiated with an Outperform at Oppenheimer
CRON Cronos Group
$5.99 /

-0.37 (-5.82%)

03/31/20 Canaccord
Cronos Group downgraded to Sell at Canaccord
03/31/20 Canaccord
Cronos Group downgraded to Sell from Hold at Canaccord
03/04/20
Fly Intel: Top five analyst upgrades
03/04/20 MKM Partners
Cronos Group upgraded to Buy from Neutral at MKM Partners
Downgrade
Venus Concept downgraded to Perform at Oppenheimer as COVID-19 clouds outlook » 08:03
03/31/20
03/31
08:03
03/31/20
08:03
VERO

Venus Concept

$3.65 /

-0.05 (-1.35%)

As previously reported,…

As previously reported, Oppenheimer analyst Suraj Kalia downgraded Venus Concept to Perform from Outperform. The analyst notes that the COVID-19 situation has forced the company to pull fiscal year 2020 guidance, therefore leaving a level of uncertainty in numbers. While Kalia believes in this CEO and business model, the current uncertainty in outlook forces the analyst to tactically move to the sidelines and wait till the environment stabilizes.

ShowHide Related Items >><<
VERO Venus Concept
$3.65 /

-0.05 (-1.35%)

03/31/20 Oppenheimer
Venus Concept downgraded to Perform from Outperform at Oppenheimer
01/09/20 Oppenheimer
Oppenheimer says has 'fundamentally positive' stance on Venus Concept
01/09/20 Oppenheimer
Venus Concept initiated with an Outperform at Oppenheimer
01/09/20 Maxim
Venus Concept upgraded to Buy from Hold at Maxim
Downgrade
Venus Concept downgraded to Perform from Outperform at Oppenheimer » 06:51
03/31/20
03/31
06:51
03/31/20
06:51
VERO

Venus Concept

$3.65 /

-0.05 (-1.35%)

Oppenheimer analyst Suraj…

Oppenheimer analyst Suraj Kalia downgraded Venus Concept to Perform from Outperform.

ShowHide Related Items >><<
VERO Venus Concept
$3.65 /

-0.05 (-1.35%)

01/09/20 Oppenheimer
Oppenheimer says has 'fundamentally positive' stance on Venus Concept
01/09/20 Oppenheimer
Venus Concept initiated with an Outperform at Oppenheimer
01/09/20 Maxim
Venus Concept upgraded to Buy from Hold at Maxim
Earnings
Venus Concept reports Q4 EPS ($1.07), consensus (41c) » 16:12
03/30/20
03/30
16:12
03/30/20
16:12
VERO

Venus Concept

$3.65 /

-0.055 (-1.49%)

Reports Q4 revenue…

Reports Q4 revenue $31.9M, consensus $32.71M. "2019 was a year of significant advancement and change for Venus Concept," said Domenic Serafino, Chief Executive Officer of Venus Concept. "We delivered solid commercial execution, received new regulatory clearances and launched two new products in the U.S., and a total of four in international markets; we closed our merger transaction on November 7, 2019 and we made significant progress in enhancing our financial condition with multiple financing transactions. The integration of our two companies is progressing rapidly and we remain excited by the long-term prospects of both the combined global commercial team, and the potentially powerful combination of Venus' expertise in non-invasive energy-based technologies for aesthetic applications and Restoration Robotics' expertise in robotic technology, 3D pre-operative planning and software. We ended the year by delivering fourth quarter revenue, giving effect to the merger for the full year, at the high-end of our preliminary range, driven by 2% growth in the legacy Venus Concept business, which offset the expected softer sales performance in the former Restoration Robotics business compared to the prior year."

ShowHide Related Items >><<
VERO Venus Concept
$3.65 /

-0.055 (-1.49%)

01/09/20 Oppenheimer
Oppenheimer says has 'fundamentally positive' stance on Venus Concept
01/09/20 Oppenheimer
Venus Concept initiated with an Outperform at Oppenheimer
01/09/20 Maxim
Venus Concept upgraded to Buy from Hold at Maxim
Over a quarter ago
Hot Stocks
Venus Concept appoints Chad Zaring as CCO » 07:50
03/03/20
03/03
07:50
03/03/20
07:50
VERO

Venus Concept

$6.88 /

+0.175 (+2.61%)

, TMDI

Titan Medical

$0.38 /

+0.0089 (+2.40%)

Venus Concept (VERO)…

Venus Concept (VERO) announced that it has expanded its Executive Team with the appointment of Chad Zaring to the newly-created role of Chief Commercial Officer, effective February 10, 2020. Prior to joining the Venus Concept, Mr. Zaring served as the Chief Commercial Officer at Titan Medical (TMDI).

ShowHide Related Items >><<
VERO Venus Concept
$6.88 /

+0.175 (+2.61%)

01/09/20 Oppenheimer
Oppenheimer says has 'fundamentally positive' stance on Venus Concept
01/09/20 Oppenheimer
Venus Concept initiated with an Outperform at Oppenheimer
01/09/20 Maxim
Venus Concept upgraded to Buy from Hold at Maxim
TMDI Titan Medical
$0.38 /

+0.0089 (+2.40%)

12/23/19 Piper Sandler
Titan Medical price target cut to $1.50 from $2.50 at Piper Jaffray
11/18/19 Piper Sandler
Titan Medical transferred with an Overweight rating at Piper Jaffray
10/16/19 Maxim
Titan Medical downgraded to Hold from Buy at Maxim
05/22/19
Fly Intel: Top five analyst initiations
Hot Stocks
Venus Concept receives NeoGraft license, CE Mark approval to market Venus Bliss » 16:09
02/14/20
02/14
16:09
02/14/20
16:09
VERO

Venus Concept

$8.00 /

+0.46 (+6.10%)

Venus Concept announced…

Venus Concept announced that it has received CE Mark approval to market Venus Bliss for non-invasive lipolysis of the abdomen and flanks, skin tightening, circumferential reduction and cellulite reduction and a medical device license issued by Health Canada to market NeoGraft 2.0 for hair restoration. Venus Bliss is a non-invasive medical aesthetic device that offers a comprehensive solution to fat reduction and cellulite reduction with two technologies in one system. The system uses the company's proprietary technology which combines multi-polar radio frequency and pulsed electro magnetic fields with advanced VariPulse technology. The Venus Bliss treats focal fat in the abdomen and flanks through non-invasive lipolysis, resulting in circumferential reduction. The Venus Bliss treatment leverages the applicator technology to tighten lax skin and to reduce the appearance of cellulite.

ShowHide Related Items >><<
VERO Venus Concept
$8.00 /

+0.46 (+6.10%)

01/09/20 Oppenheimer
Oppenheimer says has 'fundamentally positive' stance on Venus Concept
01/09/20 Oppenheimer
Venus Concept initiated with an Outperform at Oppenheimer
01/09/20 Maxim
Venus Concept upgraded to Buy from Hold at Maxim
Syndicate
Venus Concept files to sell 16.39M shares of common stock for holders  17:06
01/31/20
01/31
17:06
01/31/20
17:06
VERO

Venus Concept

$6.97 /

-0.3 (-4.13%)

 
ShowHide Related Items >><<
VERO Venus Concept
$6.97 /

-0.3 (-4.13%)

01/09/20 Oppenheimer
Oppenheimer says has 'fundamentally positive' stance on Venus Concept
01/09/20 Oppenheimer
Venus Concept initiated with an Outperform at Oppenheimer
01/09/20 Maxim
Venus Concept upgraded to Buy from Hold at Maxim
Hot Stocks
Fly Intel: After Hours Movers » 18:26
01/09/20
01/09
18:26
01/09/20
18:26
SNX

Synnex

$128.67 /

+1.44 (+1.13%)

, ACRS

Aclaris Therapeutics

$1.87 /

+ (+0.00%)

, MRNA

Moderna

$18.39 /

+0.42 (+2.34%)

, RARE

Ultragenyx

$43.64 /

-1.485 (-3.29%)

, VERO

Venus Concept

$5.67 /

+0.76 (+15.48%)

, ISRG

Intuitive Surgical

$585.69 /

+4.35 (+0.75%)

, KBH

KB Home

$37.06 /

+0.06 (+0.16%)

, PTLA

Portola Pharmaceuticals

$24.73 /

+0.74 (+3.08%)

, SPWH

Sportsman's Warehouse

$7.97 /

-0.67 (-7.75%)

, URBN

Urban Outfitters

$27.69 /

-0.79 (-2.77%)

, GRUB

GrubHub

$55.80 /

+1.1 (+2.01%)

UP AFTER EARNINGS: Synnex…

UP AFTER EARNINGS: Synnex (SNX), up 7.9%. ALSO HIGHER: Aclaris Therapeutics (ACRS), up 24.2% after announcing "positive" results from its Phase 1 trial of ATI-450... Moderna (MRNA), up 20.4% after reporting "positive" safety and immunogenicity Phase 1 data from its CMV vaccine study... Ultragenyx (RARE), up 17.9% after reporting data on Cohort 3 and 2 from study of DTX301... Venus Concept (VERO), up 6% after Oppenheimer initiated coverage on the stock with an Outperform rating... Intuitive Surgical (ISRG), up 2.3% after reporting preliminary Q4 revenue above estimates. DOWN AFTER EARNINGS: KB Home (KBH), down 2%. ALSO LOWER: Portola Pharmaceuticals (PTLA), down 39.4% after announcing preliminary Andexx net revenues for Q4... Sportsman's Warehouse (SPWH), down 16% after providing guidance for Q4 and fiscal 2019... Urban Outfitters (URBN), down 9.7% after reporting holiday sales... GrubHub (GRUB), down 7.8% after Bloomberg said the company isn't running a sale process.

ShowHide Related Items >><<
SNX Synnex
$128.67 /

+1.44 (+1.13%)

12/23/19 Citi
Citi names Amphenol top pick, cuts Celestica to Sell into 'Year of Connectivity'
09/06/19 BofA
Synnex initiated with a Buy at BofA/Merrill
04/12/19 Citi
Synnex price target raised to $140 from $130 at Citi
04/04/19
Fly Intel: Top five analyst initiations
ACRS Aclaris Therapeutics
$1.87 /

+ (+0.00%)

10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform from Market Perform at SVB Leerink
10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform at SVB Leerink
10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform from Market Perform at SVB Leerink
10/11/19 William Blair
William Blair sees 'significant value disconnect' in Aclaris Therapeutics
MRNA Moderna
$18.39 /

+0.42 (+2.34%)

12/03/19 BofA
Moderna resumed with a Buy at BofA/Merrill
10/25/19 Roth Capital
Moderna initiated with a Buy at Roth Capital
09/13/19 Piper Sandler
Moderna price target raised to $32 from $30 at Piper Jaffray
08/16/19 Piper Sandler
Moderna should be bought ahead of catalysts, says Piper Jaffray
RARE Ultragenyx
$43.64 /

-1.485 (-3.29%)

12/18/19 Piper Sandler
Piper remains buyer of Ultragenyx after Royalty Pharma deal
11/27/19 Cowen
Ultragenyx weakness a buying opportunity, says Cowen
09/04/19 SVB Leerink
Ultragenyx price target raised to $85 from $80 at SVB Leerink
09/04/19 Piper Sandler
Ultragenyx announced positive DTX401 update, says Piper Jaffray
VERO Venus Concept
$5.67 /

+0.76 (+15.48%)

01/09/20 Oppenheimer
Oppenheimer says has 'fundamentally positive' stance on Venus Concept
01/09/20 Maxim
Venus Concept upgraded to Buy from Hold at Maxim
ISRG Intuitive Surgical
$585.69 /

+4.35 (+0.75%)

01/09/20 JPMorgan
Danaher, Thermo named JPMorgan's top 2020 picks in Life Science Tools
01/07/20 Deutsche Bank
Deutsche sees sign Intuitive Surgical's U.S. procedure growth slowed in Q4
12/20/19 Piper Sandler
Intuitive Surgical competition still few years away, says Piper Jaffray
12/16/19 Piper Sandler
Congress could permanently repeal 3 health industry taxes, says Piper Jaffray
KBH KB Home
$37.06 /

+0.06 (+0.16%)

01/07/20 Raymond James
Raymond James upgrades homebuilder sector, makes three stock rating changes
01/07/20 Raymond James
KB Home upgraded to Strong Buy from Outperform at Raymond James
12/27/19 Wedbush
Lower homes supply should support homebuilder pricing power, says Wedbush
12/17/19 RBC Capital
KB Home, Owens Corning, Skyline price targets raised at RBC Capital
PTLA Portola Pharmaceuticals
$24.73 /

+0.74 (+3.08%)

11/08/19 Goldman Sachs
Portola Pharmaceuticals initiated with a Neutral at Goldman Sachs
08/08/19 Citi
The time to buy Portola Pharmaceuticals is now, says Citi
08/05/19
Fly Intel: Top five analyst initiations
08/05/19 Credit Suisse
Portola Pharmaceuticals assumed with a Neutral at Credit Suisse
SPWH Sportsman's Warehouse
$7.97 /

-0.67 (-7.75%)

01/06/20 Lake Street
Sportsman's Warehouse initiated with a Buy at Lake Street
12/12/19 Craig-Hallum
Sportsman's Warehouse initiated with a Buy at Craig-Hallum
12/05/19 Piper Sandler
Sportsman's Warehouse price target raised to $11 from $8 at Piper Jaffray
10/02/19 Piper Sandler
Sportsman's Warehouse price target raised to $8 from $7 at Piper Jaffray
URBN Urban Outfitters
$27.69 /

-0.79 (-2.77%)

12/16/19
Fly Intel: Top five analyst downgrades
12/16/19 Loop Capital
Urban Outfitters downgraded to Hold from Buy at Loop Capital
12/16/19 Loop Capital
Urban Outfitters downgraded to Hold from Buy at Loop Capital
11/20/19 Loop Capital
Urban Outfitters price target lowered to $28 from $35 at Loop Capital
GRUB GrubHub
$55.80 /

+1.1 (+2.01%)

01/09/20 JMP Securities
Uber the most likely buyer if GrubHub gets sold, says JMP Securities
01/09/20 Deutsche Bank
GrubHub could be worth 'substantially higher' in buyout, says Deutsche Bank
01/09/20 Wedbush
GrubHub price target raised to $45 from $30 at Wedbush
01/08/20 Stifel
GrubHub's reported strategic review 'seems prudent,' says Stifel

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.